Trial Profile
Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms FIRE-4.5
- 14 Feb 2024 Status changed from active, no longer recruiting to completed.
- 20 May 2021 According to Merck media release, data from this trial will be presented at this years American Society of Clinical Oncology (ASCO) Annual Meeting
- 10 Jan 2017 New trial record